Skip to search formSkip to main contentSkip to account menu

labetuzumab

Known as: monoclonal antibody hMN-14, hMN-14, MAb hMN14 
A humanized monoclonal antibody that recognizes carcinoembryonic antigen.
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing…
2505 Background: Combination chemotherapies with 5-FU, irinotecan, oxaliplatin, anti-VEGF, and anti-EGFR agents have improved the… 
2013
2013
Abstract LB-159: A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC).
Background: IMMU-130 is an ADC comprising the humanized monoclonal IgG antibody (mAb), hMN-14 (labetuzumab), bound to the active… 
2010
2010
Abstract 2438: Efficacious therapies of two human pancreatic cancer xenografts and an aggressive human lymphoma xenograft with redesigned antibody-SN-38 conjugates
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Antibody (MAb) conjugates of the potent… 
2008
2008
Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM)
4080 Background: Within a phase-II study a single dose RAIT (40–60 mCi/m2131iodine-labetuzumab, Immunomedics, Inc., Morris Plains… 
2005
2005
Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
Purpose: A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for cancer therapy is the short retention… 
2005
2005
Radioimmunotherapy for Colorectal Cancer
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for… 
1999
1999
Generation and monitoring of cell lines producing humanized antibodies.
Antibody humanization has eliminated or reduced the human antimouse antibody response associated with the administration of… 
Highly Cited
1997
Highly Cited
1997
Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
UNLABELLED In this study, we examined the factors that may influence tumor dosimetry in the radioimmunotherapy of solid, CEA… 
1995
1995
Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.
A natural N-linked glycosylation site (Asn-Val-Thr) at amino acid positions 18-20 (Kabat's numbering) was identified in the… 
1995
1995
Bacterial expression of a kemptide fusion protein facilitates 32P labeling of a humanized, anti-carcinoembryonic antigen (hMN-14) antibody fragment.
Despite the potential advantages of 32P over other isotopes for radioimmunotherapy, its development as a therapeutic has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)